Do analysts rate BWAY or INGN?

Brainsway currently has a consensus target price of $18.20, suggesting a potential upside of 33.73%. Given Brainsway's stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainsway is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainsway 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, BWAY or INGN?

Brainsway has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $60.70M 9.02 $7.57M $0.44 30.93 Inogen $348.67M 0.39 -$22.75M -$0.90 N/A

Is BWAY or INGN more profitable?

Brainsway has a net margin of 15.65% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.74% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.65% 12.74% 8.17% Inogen -6.94% -13.17% -8.36%

Does the media prefer BWAY or INGN?

In the previous week, Brainsway and Brainsway both had 1 articles in the media. Brainsway's average media sentiment score of 1.76 beat Inogen's score of 0.00 indicating that Brainsway is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INGN or DCTH?

Delcath Systems has a consensus price target of $23.17, indicating a potential upside of 43.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Delcath Systems 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has higher earnings and valuation, INGN or DCTH?

Delcath Systems has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.39 -$22.75M -$0.90 N/A Delcath Systems $95.42M 5.86 $2.70M $0.01 1,611.00

Is INGN or DCTH more profitable?

Delcath Systems has a net margin of 0.56% compared to Inogen's net margin of -6.94%. Delcath Systems' return on equity of 0.46% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% Delcath Systems 0.56% 0.46% 0.42%

Does the media refer more to INGN or DCTH?

In the previous week, Inogen and Inogen both had 1 articles in the media. Delcath Systems' average media sentiment score of 0.26 beat Inogen's score of 0.00 indicating that Delcath Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INGN or TCMD?

Tactile Systems Technology has a consensus target price of $38.40, indicating a potential upside of 72.97%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts plainly believe Tactile Systems Technology is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tactile Systems Technology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media favor INGN or TCMD?

In the previous week, Inogen and Inogen both had 1 articles in the media. Inogen's average media sentiment score of 0.00 equaled Tactile Systems Technology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tactile Systems Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NPCE or INGN?

NeuroPace currently has a consensus price target of $19.33, indicating a potential upside of 35.39%. Given NeuroPace's stronger consensus rating and higher possible upside, research analysts plainly believe NeuroPace is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroPace 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.90 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, NPCE or INGN?

NeuroPace has higher earnings, but lower revenue than Inogen. NeuroPace is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $106.99M 4.58 -$21.47M -$0.57 N/A Inogen $348.67M 0.39 -$22.75M -$0.90 N/A

Is NPCE or INGN more profitable?

Inogen has a net margin of -6.94% compared to NeuroPace's net margin of -19.34%. Inogen's return on equity of -13.17% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -19.34% -105.64% -16.51% Inogen -6.94% -13.17% -8.36%

Does the media prefer NPCE or INGN?

In the previous week, NeuroPace had 2 more articles in the media than Inogen. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for Inogen. NeuroPace's average media sentiment score of 0.47 beat Inogen's score of 0.00 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INGN or SGHT?

Sight Sciences has a consensus target price of $7.88, indicating a potential downside of 1.81%. Given Sight Sciences' higher possible upside, analysts plainly believe Sight Sciences is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Sight Sciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, INGN or SGHT?

Inogen has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.39 -$22.75M -$0.90 N/A Sight Sciences $77.36M 5.71 -$38.43M -$0.56 N/A

Is INGN or SGHT more profitable?

Inogen has a net margin of -6.94% compared to Sight Sciences' net margin of -35.69%. Inogen's return on equity of -13.17% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% Sight Sciences -35.69% -43.39% -22.86%

Does the media refer more to INGN or SGHT?

In the previous week, Sight Sciences had 3 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Sight Sciences and 1 mentions for Inogen. Sight Sciences' average media sentiment score of 0.26 beat Inogen's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Inogen (INGN) Competitors

$5.14 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.16 +0.02 (+0.31%)

As of 07:02 AM Eastern

Compare

INGN vs. BWAY, DCTH, TCMD, NPCE, and SGHT

Should you buy Inogen stock or one of its competitors? Inogen's main competitors and comparable companies include Brainsway (BWAY), Delcath Systems (DCTH), Tactile Systems Technology (TCMD), NeuroPace (NPCE), and Sight Sciences (SGHT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Inogen compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Brainsway has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$60.70M	9.02	$7.57M	$0.44	30.93
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A

In the previous week, Brainsway and Brainsway both had 1 articles in the media. Brainsway's average media sentiment score of 1.76 beat Inogen's score of 0.00 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.1% of Brainsway shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Brainsway has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Inogen has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Brainsway has a net margin of 15.65% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.74% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
Inogen	-6.94%	-13.17%	-8.36%

Brainsway currently has a consensus target price of $18.20, suggesting a potential upside of 33.73%. Given Brainsway's stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainsway is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Brainsway beats Inogen on 12 of the 16 factors compared between the two stocks.

How does Inogen compare to Delcath Systems?

Inogen (NASDAQ:INGN) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Delcath Systems has a net margin of 0.56% compared to Inogen's net margin of -6.94%. Delcath Systems' return on equity of 0.46% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Delcath Systems	0.56%	0.46%	0.42%

Delcath Systems has a consensus price target of $23.17, indicating a potential upside of 43.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

89.9% of Inogen shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inogen and Inogen both had 1 articles in the media. Delcath Systems' average media sentiment score of 0.26 beat Inogen's score of 0.00 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inogen has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Delcath Systems has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A
Delcath Systems	$95.42M	5.86	$2.70M	$0.01	1,611.00

Summary

Delcath Systems beats Inogen on 12 of the 15 factors compared between the two stocks.

How does Inogen compare to Tactile Systems Technology?

Inogen (NASDAQ:INGN) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, Inogen and Inogen both had 1 articles in the media. Inogen's average media sentiment score of 0.00 equaled Tactile Systems Technology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tactile Systems Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tactile Systems Technology has a consensus target price of $38.40, indicating a potential upside of 72.97%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts plainly believe Tactile Systems Technology is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Inogen has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

89.9% of Inogen shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tactile Systems Technology has a net margin of 7.10% compared to Inogen's net margin of -6.94%. Tactile Systems Technology's return on equity of 11.49% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Tactile Systems Technology	7.10%	11.49%	9.17%

Tactile Systems Technology has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A
Tactile Systems Technology	$329.52M	1.53	$19.09M	$1.08	20.56

Summary

Tactile Systems Technology beats Inogen on 10 of the 15 factors compared between the two stocks.

How does Inogen compare to NeuroPace?

NeuroPace (NASDAQ:NPCE) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

NeuroPace currently has a consensus price target of $19.33, indicating a potential upside of 35.39%. Given NeuroPace's stronger consensus rating and higher possible upside, research analysts plainly believe NeuroPace is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

NeuroPace has higher earnings, but lower revenue than Inogen. NeuroPace is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$106.99M	4.58	-$21.47M	-$0.57	N/A
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A

In the previous week, NeuroPace had 2 more articles in the media than Inogen. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for Inogen. NeuroPace's average media sentiment score of 0.47 beat Inogen's score of 0.00 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Inogen has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 19.2% of NeuroPace shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Inogen has a net margin of -6.94% compared to NeuroPace's net margin of -19.34%. Inogen's return on equity of -13.17% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Inogen	-6.94%	-13.17%	-8.36%

Summary

NeuroPace beats Inogen on 11 of the 17 factors compared between the two stocks.

How does Inogen compare to Sight Sciences?

Inogen (NASDAQ:INGN) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, Sight Sciences had 3 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Sight Sciences and 1 mentions for Inogen. Sight Sciences' average media sentiment score of 0.26 beat Inogen's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inogen has a net margin of -6.94% compared to Sight Sciences' net margin of -35.69%. Inogen's return on equity of -13.17% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Sight Sciences	-35.69%	-43.39%	-22.86%

Inogen has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A
Sight Sciences	$77.36M	5.71	-$38.43M	-$0.56	N/A

89.9% of Inogen shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sight Sciences has a consensus target price of $7.88, indicating a potential downside of 1.81%. Given Sight Sciences' higher possible upside, analysts plainly believe Sight Sciences is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Inogen has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

Summary

Inogen and Sight Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$136.42M	$5.49B	$7.22B	$12.94B
Dividend Yield	N/A	1.80%	2.57%	12.80%
P/E Ratio	-5.71	25.33	275.50	25.40
Price / Sales	0.39	72.63	649.31	81.48
Price / Cash	N/A	33.11	28.13	34.74
Price / Book	0.73	5.90	10.64	6.32
Net Income	-$22.75M	$151.55M	$3.49B	$358.20M
7 Day Performance	-1.72%	0.21%	-0.27%	0.42%
1 Month Performance	-8.38%	-3.86%	-2.70%	-3.30%
1 Year Performance	-40.65%	6.82%	18.14%	5.33%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	0.6235 of 5 stars	$5.14 flat	N/A	-40.6%	$136.42M	$348.67M	N/A	753	News Coverage
BWAY Brainsway	4.7187 of 5 stars	$13.63 -2.2%	$18.20 +33.5%	+76.0%	$560.10M	$52.22M	30.98	129	Positive News
DCTH Delcath Systems	2.8029 of 5 stars	$16.44 +3.3%	$23.17 +40.9%	+39.6%	$552.06M	$95.42M	1,645.65	156
TCMD Tactile Systems Technology	3.3425 of 5 stars	$22.57 +0.8%	$38.40 +70.1%	+57.9%	$507.41M	$329.52M	20.90	1,086	Positive News
NPCE NeuroPace	3.235 of 5 stars	$14.59 +3.9%	$19.29 +32.2%	+43.7%	$481.91M	$106.99M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors

INGN vs. BWAY, DCTH, TCMD, NPCE, and SGHT

How does Inogen compare to Brainsway?

Summary

How does Inogen compare to Delcath Systems?

Summary

How does Inogen compare to Tactile Systems Technology?

Summary

How does Inogen compare to NeuroPace?

Summary

How does Inogen compare to Sight Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inogen (INGN) Competitors

INGN vs. BWAY, DCTH, TCMD, NPCE, and SGHT

How does Inogen compare to Brainsway?

Which has stronger earnings & valuation, BWAY or INGN?

Does the media prefer BWAY or INGN?

Do institutionals and insiders have more ownership in BWAY or INGN?

Which has more risk & volatility, BWAY or INGN?

Is BWAY or INGN more profitable?

Do analysts rate BWAY or INGN?

Summary

How does Inogen compare to Delcath Systems?

Is INGN or DCTH more profitable?

Do analysts prefer INGN or DCTH?

Do institutionals & insiders believe in INGN or DCTH?

Does the media refer more to INGN or DCTH?

Which has more risk & volatility, INGN or DCTH?

Which has higher earnings and valuation, INGN or DCTH?

Summary

How does Inogen compare to Tactile Systems Technology?

Does the media favor INGN or TCMD?

Do analysts recommend INGN or TCMD?

Which has more risk & volatility, INGN or TCMD?

Do insiders and institutionals believe in INGN or TCMD?

Is INGN or TCMD more profitable?

Which has stronger earnings and valuation, INGN or TCMD?

Summary

How does Inogen compare to NeuroPace?

Do analysts recommend NPCE or INGN?

Which has higher earnings & valuation, NPCE or INGN?

Does the media prefer NPCE or INGN?

Which has more volatility & risk, NPCE or INGN?

Do institutionals & insiders have more ownership in NPCE or INGN?

Is NPCE or INGN more profitable?

Summary

How does Inogen compare to Sight Sciences?

Does the media refer more to INGN or SGHT?

Is INGN or SGHT more profitable?

Which has higher earnings & valuation, INGN or SGHT?

Do institutionals and insiders believe in INGN or SGHT?

Do analysts recommend INGN or SGHT?

Which has more volatility and risk, INGN or SGHT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools